Live Markets »News & Advice»Market News»Market News Details
Market News Details
Back

Lupin gets four observations from USFDA for pharmacovigilance inspection

Press Trust of India/New Delhi 14 May 19 | 11:45 AM

Drug firm Lupin on Tuesday said it has received four observations in the establishment inspection report (EIR) given by the US health regulator following the closure of pharmacovigilance inspection.

"The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin's marketed products worldwide. The inspection closed with four observations," the company said in a regulatory filing.

Related Stories

    No Related Stories Found
Widgets Magazine

Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the post-marketing adverse drug experience (PADE) inspection, indicating successful closure of the inspection, the filing added.

ALSO READ: Lupin gets govt nod for more time to complete project in Indore SEZ

The inspection was conducted at its global pharmacovigilance group DSRM (Drug Safety & Risk Management) based out of Mumbai between January 14-18, 2019, Lupin said.

The USFDA issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection following the closure of the inspection.

Shares of Lupin Ltd were trading 0.18 per cent higher at Rs 802.80 apiece on BSE.

Widgets Magazine

Sensex

Company Price Gain (%)
NTPC129.852.20
Coal India221.950.68
TCS2,076.950.55
O N G C144.100.42
Power Grid Corpn205.900.27

Poll

Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine